Test Catalog

Test Id : MURA

Order This Test

Lysozyme (Muramidase), Plasma

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

As a screening test for ocular sarcoidosis

 

Confirming marked increases in the granulocyte or monocyte pools as in granulocytic or monocytic leukemias, myeloproliferative disorders, and malignant histiocytosis

 

Following the course of therapy in cases of chronic granulocytic or chronic monocytic leukemias

Method Name
A short description of the method used to perform the test

Turbidimetric

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Lysozyme (Muramidase), P

Aliases
Lists additional common names for a test, as an aid in searching

Muramidase

Specimen Type
Describes the specimen type validated for testing

Plasma EDTA

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Collection Instructions:

1. Centrifuge and aliquot plasma into a plastic vial within 2 hours of collection.

2. Freeze immediately after transferring.

Forms

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

1 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen 21 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

As a screening test for ocular sarcoidosis

 

Confirming marked increases in the granulocyte or monocyte pools as in granulocytic or monocytic leukemias, myeloproliferative disorders, and malignant histiocytosis

 

Following the course of therapy in cases of chronic granulocytic or chronic monocytic leukemias

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Lysozyme is a bacteriolytic enzyme that is found in some hematopoietic cells. It is primarily present in granulocytes, monocytes, and histiocytes. The enzyme is present in only minute amounts in lymphocytes; and is not present in myeloblasts, eosinophils, and basophils.

 

Lysozyme in the plasma comes chiefly from the degradation of granulocytes and monocytes and its concentration reflects the turnover of these cells. Increases are seen in benign (eg, infection, inflammation) and malignant processes (eg, some leukemias). Plasma lysozyme is elevated in patients with acute or chronic granulocytic or monocytic leukemias and falls with successful treatment. Conversely, patients with lymphocytic leukemia may have depressed plasma lysozyme levels.

 

Patients with kidney disorders (including rejection of transplanted kidneys) or Crohn disease (regional enteritis) also tend to have elevated levels of plasma lysozyme.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =12 months: 2.6-6.0 mcg/mL

Reference values have not been established for patients who are less than12 months of age.

Interpretation
Provides information to assist in interpretation of the test results

Levels above 200 mcg/mL may be seen in acute nonlymphocytic leukemia (M2, M4, M5) or chronic granulocytic leukemias.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Increased levels may be seen in nonmalignant disorders including sarcoidosis, infections, Crohn's disease, kidney transplant rejection, and other kidney disorders.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Catovsky D, Galton DA, Griffin C. The significance of lysozyme estimations in acute myeloid and chronic monocytic leukaemia. Br J Haematol. 1971;21(5):565-580

2. Herbort CP, Roa NA, Mochizuki M, members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: Results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160-169

3. Bergantini L, Bianchi F, Cameli P, et al. Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers. 2019;2019:8565423 doi:10.1155/2019/8565423

Method Description
Describes how the test is performed and provides a method-specific reference

The term lysozyme is derived from the ability of this enzyme to dissolve the walls of certain bacteria, including Micrococcus lysodeikticus. This organism is suspended in buffer, and the sample is added. The resulting decrease in turbidity is measured spectrophotometrically. The rate of clearing is a reflection of the concentration of the enzyme.(Litwack G: Photometric determination of lysozyme activity. Proc Soc Exp Biol Med. 1955;89(3):401-403)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 5 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

85549

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MURA Lysozyme (Muramidase), P 2589-0
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
MURA Lysozyme (Muramidase), P 2589-0

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | PHP Pdf | CMS Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports